Related Experiment Video

Updated: Feb 22, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.7K

[Effect of processed Polygonum multiflorum on mRNA expression level of five subtypes of CYP450 enzymes in rat liver]

Chun-Lian Huang1,2, Xue-Mei Fan2, Qian Li3

  • 1School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica
|September 27, 2017
PubMed

Insights

Processed Polygonum multiflorum affects liver enzymes in rats. High doses of this herb may cause liver damage and inhibit specific CYP450 enzyme mRNA expression, particularly CYP1A2 and CYP2E1.

Area of Science:

  • Pharmacology
  • Hepatology
  • Molecular Biology

Background:

  • Polygonum multiflorum is a traditional Chinese herb.
  • Understanding its effects on liver function and drug metabolism is crucial.

Purpose of the Study:

  • To investigate the impact of processed Polygonum multiflorum on CYP450 enzyme mRNA expression in rat liver.
  • To assess potential hepatotoxicity associated with Polygonum multiflorum administration.

Main Methods:

  • Rats were administered processed Polygonum multiflorum at high (5.40 g•kg⁻¹) and low (1.08 g•kg⁻¹) doses for 7 days.
  • Serum biochemical indicators (AST, ALT) were measured.
  • Real-time quantitative PCR was used to determine mRNA expression levels of five CYP450 enzyme subtypes.

Main Results:

  • AST levels decreased in both low and high dose groups.
  • ALT levels decreased in the low dose group but increased significantly in the high dose group.
  • mRNA expression of five CYP450 subtypes decreased dose-dependently, with significant inhibition of CYP1A2 and CYP2E1 at high doses.

Conclusions:

  • High-dose processed Polygonum multiflorum exhibits hepatotoxicity in rats, with liver damage increasing with dose.
  • Processed Polygonum multiflorum significantly inhibits CYP1A2 and CYP2E1 mRNA expression in rat liver, particularly at high concentrations.
Keywords:
CYP450liver injurymRNA expressionprocessed Polygonum multiflorumserum biochemical indicators

More Related Videos

Visualization of Endoplasmic Reticulum Localized mRNAs in Mammalian Cells10:24

Visualization of Endoplasmic Reticulum Localized mRNAs in Mammalian Cells

Published on: December 17, 2012

14.7K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.3K

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
27
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
31
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
24